Strategies for managing an outsourcing partner
Robust oversight linked to increased efficiency and better communication with outsourcing partners.
The healthcare industry has undergone a transformation over the last few decades, with an uptick in outsourcing shining through as a key trend. The benefits of outsourcing research, development or manufacturing activities are multifold – it can cut R&D costs, increase efficiency across the value chain, and allows companies to benefit from expertise they may lack in-house.
However, engaging an outsourcing partner such as a CRO or CDMO comes with its risks. According to Stephanie Gaulding, Managing Director at Pharmatech Associates, the more hands-off approach a sponsor takes, the higher the risk becomes.
Gaulding led a session on strategies for managing outsourcing partners at CPHI North America this week and emphasised the importance of creating a robust oversight framework.
‘You need to have processes in place to control quality and oversee your outsource activities,’ she told conference attendees.
‘Without these processes you can run the risk of things going awry - not having adequate oversight, not making sure that products are made in accordance with the associated regulations.’
Gaulding recommended defining activities that can be delegated early in the process, and clearly outlining these in contractual documents.
She added that the level of oversight a sponsor retains is a crucial consideration – too little can lead to delays and miscommunication, while micromanagement can result in inefficiencies.
She said: ‘What we ultimately want to do is stay in that middle range, where we have tailored oversight that is tweaked and adjusted per the conditions that you’re dealing with. That’s going to get you to optimal efficiency, that’s going to get to robust communication.’
Gaulding encouraged sponsors to create detailed oversight plans, which includes everything about the scope and nature of the engagement with the outsourcing partner. She noted that gaining familiarity with an outsourcing partner’s internal processes and systems can pay dividends, so that requirements imposed on them are manageable and more likely to result in success.
‘I’d encourage everybody to understand your partner’s processes really well, go into it with an open mind and only make adjustments where you absolutely think there needs to be an adjustment,’ she said. ‘Because you’re going to cause them to trip over themselves trying to remember all these additional requirements.’
Gaulding also advised assessing a partner’s risk points, mitigating these where possible, and enacting a change management plan.
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance